A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Healthy
Interventions
DRUG

PF-03049423

PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers

DRUG

PF-03049423

PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers

DRUG

PF-03049423

PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers

DRUG

PF-03049423

PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers

DRUG

PF-03049423

PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers

DRUG

Placebo

Placebo in oral solution, given once daily for 14 days

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY